Expanded Prescribing Rights for English Pharmacies Set for Autumn Rollout

Starting in the autumn, pharmacies across England will gain the authority to prescribe a wider range of medications, a move designed to accelerate patient care and alleviate strain on general practitioner (GP) practices and hospital services.

This expansion is part of the Pharmacy First initiative, which was originally introduced in 2024. Under the current framework, pharmacists are already permitted to prescribe treatments for conditions such as sore throats, earaches, sinusitis, shingles, impetigo, infected bites, and urinary tract infections. Patients can also utilize pharmacy services for advice, over-the-counter remedies, and prescription-only medicines, alongside care for eye, ear, oral, and dental issues, as well as digestive complaints.

The government has announced a £340 million investment to add five additional common ailments to the list of treatable conditions from the autumn. However, specific details regarding these new conditions have not yet been released.

To support this expansion, thousands of newly qualified pharmacists who hold prescribing qualifications will join the workforce in the autumn. This inaugural cohort will be the first to have prescribing integrated into their pharmacy education, and they are expected to play a key role in widening and enhancing the scope of the Pharmacy First scheme.

Stephen Kinnock, the Health Minister, emphasized the strategic value of this shift. “The government is making the most of our highly skilled pharmacists, while boosting access to services and giving patients more care right on their doorstep,” he stated. He added that independent prescribing would be central to reducing pressure on GPs, minimizing administrative burdens, and ensuring patients receive appropriate treatment closer to home.

Data from the Department of Health and Social Care highlights the scheme's current reach, noting that over 3.3 million consultations took place between March 2025 and February 2026.

Despite the government’s optimism, industry leaders have expressed reservations. The National Pharmacy Association (NPA) acknowledged that the deal “points in the right direction” but argued it fails to tackle significant financial challenges facing the sector, including rising business rates, employer costs, and medicine prices.

Dr. Olivier Picard, chairman of the NPA, criticized the funding levels, stating they do little to bridge the £2.5 billion funding gap identified by the NHS a year prior. He warned that the expanded scheme is “nowhere near ambitious enough to transform patient access to care, nor make full use of pharmacists' skills.” Dr. Picard further cautioned that current funding may leave many pharmacies unable to sustain the additional workload, risking the program's overall success.

Echoing these concerns, Dr. Leyla Hannbeck, chief executive of the Independent Pharmacies Association, which represents approximately 5,000 pharmacies in England and Wales, told BBC Radio 4’s Today programme that the funding offered does not adequately cover the required workload. She noted that many pharmacists are worried about their financial viability, describing a situation where professionals are struggling to “keep their heads above the water.”

The English Pharmacy First model was inspired by a similar system in Scotland, which is regarded as the benchmark for such initiatives. Both Northern Ireland and Wales also operate systems that allow pharmacies to treat patients for specific conditions.

Source: BBC News Generated at: 2026-05-29 10:03:28 UTC